Raiffeisen Bank International AG Invests $1.57 Million in IQVIA Holdings Inc. (NYSE:IQV)

Raiffeisen Bank International AG purchased a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 7,960 shares of the medical research company's stock, valued at approximately $1,572,000.

Other hedge funds also recently added to or reduced their stakes in the company. Smith Group Asset Management LLC bought a new position in shares of IQVIA during the 4th quarter worth $1,616,000. Hickory Asset Management Inc. purchased a new position in IQVIA in the fourth quarter worth $941,000. Fifth Third Bancorp grew its holdings in IQVIA by 13.0% in the fourth quarter. Fifth Third Bancorp now owns 13,179 shares of the medical research company's stock worth $2,590,000 after purchasing an additional 1,521 shares during the last quarter. Graphene Investments SAS raised its holdings in shares of IQVIA by 22.0% in the fourth quarter. Graphene Investments SAS now owns 15,000 shares of the medical research company's stock worth $2,948,000 after buying an additional 2,700 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in shares of IQVIA by 46.2% during the third quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company's stock worth $437,378,000 after buying an additional 583,396 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

IQV stock traded up $1.36 during mid-day trading on Tuesday, reaching $144.90. 4,613,523 shares of the company's stock were exchanged, compared to its average volume of 1,536,363. The company has a market cap of $25.07 billion, a price-to-earnings ratio of 19.32, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. The stock's 50 day moving average is $158.99 and its 200 day moving average is $185.26. The company has a debt-to-equity ratio of 2.12, a current ratio of 0.84 and a quick ratio of 0.84. IQVIA Holdings Inc. has a 12-month low of $135.97 and a 12-month high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.63 by $0.07. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. The business had revenue of $3.83 billion for the quarter, compared to the consensus estimate of $3.77 billion. During the same period last year, the firm posted $2.54 earnings per share. The company's revenue was up 2.5% compared to the same quarter last year. On average, research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

IQV has been the subject of a number of research analyst reports. Stifel Nicolaus reduced their target price on IQVIA from $273.00 to $261.00 and set a "buy" rating for the company in a research note on Friday, February 7th. Barclays reduced their price objective on IQVIA from $170.00 to $165.00 and set an "equal weight" rating for the company in a research note on Wednesday, May 7th. BTIG Research lowered IQVIA from a "buy" rating to a "neutral" rating in a research report on Monday, February 3rd. UBS Group cut their price target on shares of IQVIA from $255.00 to $185.00 and set a "buy" rating on the stock in a report on Wednesday, May 7th. Finally, HSBC downgraded shares of IQVIA from a "buy" rating to a "hold" rating and cut their price target for the stock from $260.00 to $160.00 in a report on Friday, April 25th. Eight research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, IQVIA has an average rating of "Moderate Buy" and a consensus price target of $228.14.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.